Dulaglutide HIC Purification with Gradient Elution and Resin Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for purifying recombinant Fc-containing proteins like dulaglutide are inefficient in removing host cell contaminants and require frequent replacement of chromatography resins, leading to high costs and process inefficiencies.
Innovation Solution
A method utilizing hydrophobic interaction chromatography (HIC) with specific buffer compositions and operational parameters, including loading, washing, and eluting steps, to purify dulaglutide, enhancing resin lifetime and purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chromatography methods are used for dulaglutide purification, then the purification process can be completed, but host cell contaminants are not effectively removed and resin lifetime is limited
Solution Approach 1:
The patent applies parameter changes by optimizing buffer composition (pH, ionic strength, additives), flow rates, and temperature conditions during chromatography to enhance both purification effectiveness and resin durability. Specific buffer conditions are tuned to minimize resin degradation while maximizing contaminant removal.
Solution Approach 2:
The patent implements dynamic control of chromatography parameters including variable flow rates, stepwise buffer gradient changes, and real-time monitoring of purification metrics to adapt conditions during the process, thereby extending resin life while maintaining high purification performance.
2Productivity
If conventional chromatography resins are used, then the purification process can proceed, but frequent resin replacement is required leading to high costs and process inefficiency
Solution Approach 1:
The patent applies preliminary action by pre-conditioning resins with specific buffer treatments and protective agents before use, and implementing preventive maintenance protocols during operation to prevent resin degradation and extend service life, reducing both replacement frequency and downtime.
Solution Approach 2:
The patent implements resin recovery and regeneration protocols where used resins are cleaned, reconditioned, and reused through controlled chemical treatments and storage conditions, thereby extending resin lifetime and reducing replacement frequency and associated costs.
3Manufacturing precision
If conventional purification methods are used, then the process can be completed, but impurity levels remain high (30-70 ppm) affecting product quality
Solution Approach 1:
The patent applies segmentation by dividing the purification process into multiple sequential chromatography steps with different resin types and buffer conditions, where each step targets specific impurity classes, achieving high overall purity (reducing to 2-11 ppm) through cumulative effect of individual steps.
Solution Approach 2:
The patent uses composite chromatography approaches combining different resin materials with complementary selectivity properties in sequence or combination, where each resin material targets specific contaminant types, achieving comprehensive impurity removal while managing process complexity through systematic design.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The HIC method effectively removes host cell proteins and impurities, increasing dulaglutide purity to 95% and extending resin lifespan, reducing production costs and downtime.
Implementation Method 1
hydrophobic interaction chromatography (HIC) column
Data Source
AI summary
The present disclosure is directed to methods of purifying a dulaglutide composition. For example, the methods comprise loading the dulaglutide composition in-line with a buffer B solution onto a hydrophobic interaction chromatography (HIC) column in a downflow direction, washing the HIC column with a buffer mixture of a buffer A solution and the buffer B solution in the downflow direction, and eluting dulaglutide from the HIC column. A linear gradient of a percentage of the buffer A and buffer B solutions is used for eluting dulaglutide, which is then followed by an isocratic hold based on a UV absorbance reading of an eluate. The methods further comprise maintaining the isocratic hold until a front side cut is made, and then dropping the buffer B solution for dulaglutide to elute from the HIC column.